Evaluation of favipiravir treatment before intensive care in COVID-19 patients

The purpose of this study is to investigate the healing effect of Favipiravir used in pre-intensive care treatment of patients diagnosed with COVID-19 in order to elucidate the pathogenesis and complications of coronavirus. The data regarding the clinical findings of the patients in the hospital inf...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Osman Ozudogru, Emrah Yerlikaya, Naci Omer Alayunt, Zafer Çambay
Formato:	article
Lenguaje:	ID
Publicado:	Poltekkes Kemenkes Yogyakarta 2021
Materias:	coronavirus favipiravir covid-19 intensive care pandemic Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8164a2292dce445898ae98461d4bb3fc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8164a2292dce445898ae98461d4bb3fc
record_format	dspace
spelling	oai:doaj.org-article:8164a2292dce445898ae98461d4bb3fc2021-11-13T13:29:49ZEvaluation of favipiravir treatment before intensive care in COVID-19 patients2338-56342580-019110.29238/teknolabjournal.v10i1.266https://doaj.org/article/8164a2292dce445898ae98461d4bb3fc2021-08-01T00:00:00Zhttps://teknolabjournal.com/index.php/Jtl/article/view/266https://doaj.org/toc/2338-5634https://doaj.org/toc/2580-0191The purpose of this study is to investigate the healing effect of Favipiravir used in pre-intensive care treatment of patients diagnosed with COVID-19 in order to elucidate the pathogenesis and complications of coronavirus. The data regarding the clinical findings of the patients in the hospital information system and the biochemical parameters made standard in the treatment/follow-up of COVID 19 were taken from the system and evaluated retrospectively. In addition, it was examined as a whole with mild, moderate and severe pulmonary involvement compared to CT findings. Hemogram, coagulation and biochemistry parameters used in the diagnosis and follow-up of COVID-19 were evaluated. SPSS 22.0 statistics program for Windows was used in statistical analysis to evaluate the data obtained from patient files and hospital information system. There is no definitive treatment protocol within the scope of treatment. Drug studies are currently ongoing. In this study, the first clinical findings, treatment types and recovery times of patients diagnosed with COVID-19, the healing effect of favipiravir used before intensive care were determined. Between group 1 (those who started treatment within 0-5 days) and group 2 (those who started treatment within 6-10 days), after 5 days of favipravir treatment, when serum parameters were compared, favipravir treatment was statistically significantly lower in the first group that was started early, WBC, Neutrophil, Creatine, CK, CRP, D-Dimer, PCT, LDH. By collecting the data obtained as a result of the research, early deaths can be prevented worldwide. Our study recommending alternative treatment approaches is important for the protection of patients' quality of life. In this study, when all biochemical markers were evaluated together, it was evaluated that starting Favipiravir treatment early was beneficial in treating COVID-19 disease.Osman OzudogruEmrah YerlikayaNaci Omer AlayuntZafer ÇambayPoltekkes Kemenkes Yogyakartaarticlecoronavirusfavipiravircovid-19intensive carepandemicMedicine (General)R5-920IDJurnal Teknologi Laboratorium, Vol 10, Iss 1, Pp 22-30 (2021)
institution	DOAJ
collection	DOAJ
language	ID
topic	coronavirus favipiravir covid-19 intensive care pandemic Medicine (General) R5-920
spellingShingle	coronavirus favipiravir covid-19 intensive care pandemic Medicine (General) R5-920 Osman Ozudogru Emrah Yerlikaya Naci Omer Alayunt Zafer Çambay Evaluation of favipiravir treatment before intensive care in COVID-19 patients
description	The purpose of this study is to investigate the healing effect of Favipiravir used in pre-intensive care treatment of patients diagnosed with COVID-19 in order to elucidate the pathogenesis and complications of coronavirus. The data regarding the clinical findings of the patients in the hospital information system and the biochemical parameters made standard in the treatment/follow-up of COVID 19 were taken from the system and evaluated retrospectively. In addition, it was examined as a whole with mild, moderate and severe pulmonary involvement compared to CT findings. Hemogram, coagulation and biochemistry parameters used in the diagnosis and follow-up of COVID-19 were evaluated. SPSS 22.0 statistics program for Windows was used in statistical analysis to evaluate the data obtained from patient files and hospital information system. There is no definitive treatment protocol within the scope of treatment. Drug studies are currently ongoing. In this study, the first clinical findings, treatment types and recovery times of patients diagnosed with COVID-19, the healing effect of favipiravir used before intensive care were determined. Between group 1 (those who started treatment within 0-5 days) and group 2 (those who started treatment within 6-10 days), after 5 days of favipravir treatment, when serum parameters were compared, favipravir treatment was statistically significantly lower in the first group that was started early, WBC, Neutrophil, Creatine, CK, CRP, D-Dimer, PCT, LDH. By collecting the data obtained as a result of the research, early deaths can be prevented worldwide. Our study recommending alternative treatment approaches is important for the protection of patients' quality of life. In this study, when all biochemical markers were evaluated together, it was evaluated that starting Favipiravir treatment early was beneficial in treating COVID-19 disease.
format	article
author	Osman Ozudogru Emrah Yerlikaya Naci Omer Alayunt Zafer Çambay
author_facet	Osman Ozudogru Emrah Yerlikaya Naci Omer Alayunt Zafer Çambay
author_sort	Osman Ozudogru
title	Evaluation of favipiravir treatment before intensive care in COVID-19 patients
title_short	Evaluation of favipiravir treatment before intensive care in COVID-19 patients
title_full	Evaluation of favipiravir treatment before intensive care in COVID-19 patients
title_fullStr	Evaluation of favipiravir treatment before intensive care in COVID-19 patients
title_full_unstemmed	Evaluation of favipiravir treatment before intensive care in COVID-19 patients
title_sort	evaluation of favipiravir treatment before intensive care in covid-19 patients
publisher	Poltekkes Kemenkes Yogyakarta
publishDate	2021
url	https://doaj.org/article/8164a2292dce445898ae98461d4bb3fc
work_keys_str_mv	AT osmanozudogru evaluationoffavipiravirtreatmentbeforeintensivecareincovid19patients AT emrahyerlikaya evaluationoffavipiravirtreatmentbeforeintensivecareincovid19patients AT naciomeralayunt evaluationoffavipiravirtreatmentbeforeintensivecareincovid19patients AT zafercambay evaluationoffavipiravirtreatmentbeforeintensivecareincovid19patients
_version_	1718430266086653952

Evaluation of favipiravir treatment before intensive care in COVID-19 patients

Ejemplares similares